Xiao Jin-zhong, Kondo Shizuki, Takahashi Noritoshi, Odamaki Toshitaka, Iwabuchi Noriyuki, Miyaji Kazuhiro, Iwatsuki Keiji, Enomoto Tadao
Food Research and Development Laboratory, Morinaga Milk Industry, Zama, Japan.
Int Arch Allergy Immunol. 2007;144(2):123-7. doi: 10.1159/000103223. Epub 2007 May 24.
Japanese cedar pollinosis (JCPsis) is an immunoglobulin E-mediated type I allergy caused by exposure to Japanese cedar pollen (JCP). Blood thymus and activation-regulated chemokine (TARC) levels are well known as an objective parameter for disease severity for several allergic disorders. The present study aims to evaluate the relationship between TARC levels and disease symptoms during the pollen season.
Analysis was performed of results of symptom scores and blood parameters obtained from 42 JCPsis patients who participated in a probiotic (Bifidobacterium longum BB536) intake trial in the JCP season of 2005 (January to April), using a randomized, double-blind, placebo-controlled design.
Significant increases in plasma TARC levels were observed in subjects receiving placebo (p < 0.05 in February and p < 0.01 in March), but not in subjects receiving BB536. Increased plasma TARC levels were markedly greater in subjects who experienced severe symptoms and were thus excluded early from the intervention (placebo group: n = 8; BB536 group: n = 2). Significant differences were found in changes from baseline TARC levels in February and March between the subjects where treatment was terminated early and the remaining ones. Among the remaining subjects, significant positive correlations were found as regards changed values of TARC compared to baseline in March and April with symptom scores recorded in the pollen season.
Changed values of blood TARC in the pollen season may offer promising parameters for assessing disease severity and monitoring treatment.
日本雪松花粉症(JCPsis)是一种由接触日本雪松花粉(JCP)引起的免疫球蛋白E介导的I型过敏。血液胸腺和活化调节趋化因子(TARC)水平是几种过敏性疾病疾病严重程度的客观参数,这是众所周知的。本研究旨在评估花粉季节期间TARC水平与疾病症状之间的关系。
对42名参与2005年JCP季节(1月至4月)益生菌(长双歧杆菌BB536)摄入试验的JCPsis患者的症状评分和血液参数结果进行分析,采用随机、双盲、安慰剂对照设计。
接受安慰剂的受试者血浆TARC水平显著升高(2月p < 0.05,3月p < 0.01),但接受BB536的受试者未出现这种情况。经历严重症状并因此提前退出干预的受试者血浆TARC水平升高更为明显(安慰剂组:n = 8;BB536组:n = 2)。在2月和3月,提前终止治疗的受试者与其余受试者的TARC基线水平变化存在显著差异。在其余受试者中,3月和4月与花粉季节记录的症状评分相比,TARC相对于基线的变化值之间存在显著正相关。
花粉季节血液TARC的变化值可能为评估疾病严重程度和监测治疗提供有前景的参数。